

Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations

NCT07120464

Status	RECRUITING
Sponsor	Liaoning Chengda Biotechnology CO., LTD
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (8)

- Subjects with WHO category II or III rabies exposure presenting at the study site for post-exposure prophylaxis and vaccination.
- Subjects planned to be included in the control group, aged 18 to less than 60 years old, healthy as confirmed by medical history, physical examination, and clinical judgment before vaccination.
- Subjects planned to be included in the study group who meet any of the following conditions:
- Long-term immunocompromised status due to conditions including, but not limited to: clinically confirmed primary immunodeficiency diseases; hematologic or solid organ malignancies; aplastic anemia; clinically confirmed autoimmune diseases with immunosuppressive therapy lasting 4 weeks or longer within the past 12 months prior to enrollment; history of splenectomy or other major immunologic organ removal; hematopoietic stem cell or solid organ transplantation within 2 years prior to enrollment.
- Clinically confirmed diabetes mellitus, chronic hepatitis, liver cirrhosis, chronic glomerulonephritis, nephrotic syndrome, or chronic renal insufficiency.

... and 3 more (see full listing online)

Exclusion (3)

- History of previous rabies vaccination.
- History of human immunodeficiency virus (HIV) infection.
- Other conditions deemed unsuitable for participation in the clinical study by the investigator.

Locations (1 total)

Luohu District People's Hospital., Shenzhen, Guangdong, China